NZ593653A - Treatment of inflammatory bowel diseases with mammal beta defensins - Google Patents

Treatment of inflammatory bowel diseases with mammal beta defensins

Info

Publication number
NZ593653A
NZ593653A NZ593653A NZ59365309A NZ593653A NZ 593653 A NZ593653 A NZ 593653A NZ 593653 A NZ593653 A NZ 593653A NZ 59365309 A NZ59365309 A NZ 59365309A NZ 593653 A NZ593653 A NZ 593653A
Authority
NZ
New Zealand
Prior art keywords
treatment
inflammatory bowel
bowel diseases
beta defensins
mammal beta
Prior art date
Application number
NZ593653A
Other languages
English (en)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holse Mygind
Karoline Sidelmann Brinch
Soeren Kjaerulff
Birgitte Andersen
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ593653(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of NZ593653A publication Critical patent/NZ593653A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ593653A 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins NZ593653A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4

Publications (1)

Publication Number Publication Date
NZ593653A true NZ593653A (en) 2012-09-28

Family

ID=41530820

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ593653A NZ593653A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ590468A NZ590468A (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with human beta defensin proteins 1-4

Country Status (20)

Country Link
US (4) US8232242B2 (enExample)
EP (2) EP2320930A2 (enExample)
JP (2) JP2011528333A (enExample)
KR (1) KR20110092325A (enExample)
CN (2) CN102159233A (enExample)
AP (2) AP2011005755A0 (enExample)
AR (2) AR072032A1 (enExample)
AU (1) AU2009272681A1 (enExample)
BR (2) BRPI0924481A2 (enExample)
CA (2) CA2750727A1 (enExample)
CL (1) CL2011000099A1 (enExample)
EA (2) EA201100910A1 (enExample)
IL (2) IL210715A0 (enExample)
MX (1) MX2011000568A (enExample)
NZ (2) NZ593653A (enExample)
PH (1) PH12012501542A1 (enExample)
SG (1) SG172709A1 (enExample)
TW (2) TW201004640A (enExample)
WO (1) WO2010007166A2 (enExample)
ZA (1) ZA201100461B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750727A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
AR072524A1 (es) * 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
EA201170220A1 (ru) * 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение ревматоидного артрита бета-дефенсинами млекопитающих
KR101249702B1 (ko) * 2010-06-16 2013-04-05 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
WO2013007596A2 (en) 2011-07-08 2013-01-17 Novozymes A/S Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
CN109414474B (zh) * 2016-04-29 2024-07-02 诺维信公司 肝脏、胆道和胰腺障碍的治疗
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
SG11202003868UA (en) * 2017-11-10 2020-05-28 Defensin Therapeutics Aps Maturation of mucosal defense and gut/lung function in the preterm infant
WO2019101773A2 (en) 2017-11-24 2019-05-31 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用
WO2024225153A1 (ja) * 2023-04-27 2024-10-31 サントリーホールディングス株式会社 免疫活性化用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
KR20050089827A (ko) * 2002-12-19 2005-09-08 이츠차크 힐만 항균성 펩티드 억제물을 통한 질환 치료
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US8895062B2 (en) 2006-01-24 2014-11-25 University Of Maryland, Baltimore Surface-layer protein coated microspheres and uses thereof
CA2704726A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent
CA2750727A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
EA201170220A1 (ru) 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение ревматоидного артрита бета-дефенсинами млекопитающих
AR072524A1 (es) * 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
WO2013007596A2 (en) 2011-07-08 2013-01-17 Novozymes A/S Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide

Also Published As

Publication number Publication date
AP2011005538A0 (en) 2011-02-28
US8232242B2 (en) 2012-07-31
US8802621B2 (en) 2014-08-12
MX2011000568A (es) 2011-02-23
EP2320930A2 (en) 2011-05-18
IL210715A0 (en) 2011-03-31
AR081948A2 (es) 2012-10-31
EA201170219A1 (ru) 2011-08-30
BRPI0915973A2 (pt) 2013-05-07
AU2009272681A1 (en) 2010-01-21
PH12012501542A1 (en) 2015-11-09
US20140135258A1 (en) 2014-05-15
US20100016230A1 (en) 2010-01-21
CN102247591A (zh) 2011-11-23
CN102159233A (zh) 2011-08-17
CA2730789A1 (en) 2010-01-21
BRPI0924481A2 (pt) 2015-08-11
KR20110092325A (ko) 2011-08-17
ZA201100461B (en) 2014-03-26
AR072032A1 (es) 2010-07-28
SG172709A1 (en) 2011-07-28
IL213680A0 (en) 2011-07-31
AP2011005755A0 (en) 2011-06-30
JP2011528333A (ja) 2011-11-17
EP2399600A1 (en) 2011-12-28
JP2011225596A (ja) 2011-11-10
US20120309678A1 (en) 2012-12-06
TW201004640A (en) 2010-02-01
CA2750727A1 (en) 2010-01-21
US20110251139A1 (en) 2011-10-13
TW201138810A (en) 2011-11-16
EA201100910A1 (ru) 2012-05-30
WO2010007166A3 (en) 2010-06-03
WO2010007166A2 (en) 2010-01-21
NZ590468A (en) 2012-06-29
US9279010B2 (en) 2016-03-08
CL2011000099A1 (es) 2011-10-07

Similar Documents

Publication Publication Date Title
NZ593653A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
TR201818927T4 (tr) Kataterlerde İyileştirme
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
PT2510916T (pt) Composição farmacêutica antisséptica para a higiene oral e o tratamento de doenças bucais de origem microbiana
IL220613B (en) Use of antibiotics and a probiotic formulation in the preparation of a drug for the treatment of inflammatory bowel disease
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
AP2011005537A0 (en) Treatment of inflammatory diseases with mammal beta defensins.
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
IL201479A (en) Use of tapentadol for the preparation of pain medication
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
IL191908A0 (en) Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases
IL215579A (en) Use of 1-benzyl-3-hydroxymethylindazole history to prepare medicinal products for the treatment of diseases based on the expression of 1-mcp, cx3cr1 and 40p
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
EA201170873A1 (ru) Безопасное введение десмопрессина
ZA201105320B (en) Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
NZ597675A (en) Medicament for the long term nsaid use
JP2011503050A5 (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed